You have successfully logged out.

Hello !
chevron_right My profile
chevron_right To My B. Braun overview
Logout

No content results match your keyword.

Content

    No product results match your keyword.

    Products

      Peripheral Angioplasty

      Combination therapy for endovascular procedures

      Leave almost nothing behind by using our proven SeQuent® Please OTW DCB in combination with VascuFlex® LOC multiple stent systems for spot and focal stenting.

      Undress the full metal jacket

      Combination therapy for endovascular procedures with VascuFlex® Multi-LOC and SeQuent® Please OTW

      SeQuent® Please OTW: A fruitful formulation

      Product picture of SeQuent® Please OTW

      Paclitaxel with a drug dose of 3 μg/mm²

      • Proven and effective drug dose [1]
      • Homogeneous coating even in the balloon folds [2]

       

      Resveratrol as hydrophilic excipient

      • Naturally occurring, plant based substance found e.g. in red grapes & raspberries
      • Acts as hydrophilic spacer and makes Paclitaxel bioavailable
      • Enables drug transfer into vessel wall [2]

      CONSEQUENT randomized controlled trial

      • 153 patients (78 DCB vs. 75 POBA)
      • Rutherford 2-4 (95 % Grade 3-4)
      • Diameter stenosis pre-procedure: 76.6 ± 18.1 %
      • TASC C/D lesions: 23.5 %
      • Mean lesion length 13.2 ± 10.4 cm
      • Positive remodeling (LLL <0.00 mm) in DCB group: 36.5 %
      • Predilatation: in only 55.6 % of cases
      • Bailout stenting: 16.3 % (similar in both groups)
      • Primary endpoint: 6-month angiographic late lumen loss
      • Secondary endpoints: TLR, binary restenosis (> 50 %, PSVR > 2.4), walking distance, ABI at 6, 12 and 24 months

       

      close
      CONSEQUENT randomized controlled trial: Mean lesion length table
      CONSEQUENT randomized controlled trial: 6 month late lumen loss table
      CONSEQUENT randomized controlled trial: 24 month TLR rate table
      CONSEQUENT randomized controlled trial: 24 month mean walking distance table

      VascuFlex® Multi-LOC: Spot your lesions with short stents only!

      Product picture of VascuFlex® Multi-LOC
      • Six short stents on one delivery system
      • Cover lesions only where it is really needed
      • Maintain natural vessel movement
      • Avoid full metal jackets

       

      Features

      • Short self-expanding Nitinol stents of 13 mm length each
      • Stents with high radial force for highly calcified lesions [2]
      • 5-8 mm stent diameters for SFA and popliteal arteries
      • 0.035” guidewire compatibility; 6F sheath compatibility

      LOCOMOTIVE extended study: 12-month data [8]

      • 357 patients
      • 71.1 % Rutherford stages 3 to 5
      • Lesions in SFA and popliteal artery (segments 1 to 3) with vessel diameter: 5.5 ± 1.1 mm
      • Average lesion lengths: 16.0 ± 9.7 cm
      • Calcification: 85.7 %
      • Chronic total occlusion: 31.4 %
      • TASC C&D lesions: 44.5 %
      • TLR rate at 6 months (primary endpoint): 4.5 % (Revaskularisation rate of the target lesion)
      • Secondary endpoints: TLR at 12 months, patency (Duplex ultrasound), Rutherford classification, amputation rate, ABI and walking distance at 6 and 12 months

       

      Chart of the LOCOMOTIVE extended study: 12-month data

      Learn more about related products

      SeQuent® Please OTW

      Peripheral drug coated balloon catheter

      VascuFlex® 3-LOC

      Focal stenting system

      VascuFlex® Multi-LOC

      Spot stenting system

      VascuFlex® 2-LOC

      Focal stenting system

      Get in touch with our Interventional Vascular Therapy experts

      Interventional Vascular Therapy Contact Form

      [1] Katsanos K et al. in J Endovasc Ther. 2016 Apr;23(2):356-70

      [2] Data on file at B. Braun

      [3] Albrecht T et al. Cardiovasc Intervent Radiol. 2018 Jul;41(7):1008-1014

      [4] Schröder H Catheterization and Cardiovascular Interventions, Volume 86, Issue 2 August 2015 Pages 278-286

      [5] Werk M et al. Circ Cardiovasc Interv. 2012;5(6):831-840

      [6] Scheinert D et al. JACC Cardiovasc Interv. 2014;7(1):10-19

      [7] Zeller T et al. JACC Cardiovasc Interv. 2015;8(12):1614-1622

      [8] Amendt K, et al. Vasa (2020), 1-8.doi.org/10.1024/0301-1526/a000927

      Take part in our customer survey

      Your feedback matters! Participate in our customer survey to help us enhance our website, products and services. Thank you for your support!

      Start survey